AVANT Debuts Exclusive Provider Analytics within Pathfinder 2.0 at Special Forces Summit
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023
Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented…
Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented…
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94%…
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94%…
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024…
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024…
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
Planegg/Martinsried, September 27, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology…
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a…
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a…
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
WEST CHESTER, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the…
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
LYON, France and CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) — Amolyt Pharma, a global…
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
Todd Edwards Chief Commercial Officer, Arcutis Biotherapeutics Industry veteran with deep commercial experience in dermatology…
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD…
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology…